Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
| Revenue (TTM) | $1.67B |
| Gross Profit (TTM) | $1.45B |
| EBITDA | $284.93M |
| Operating Margin | 15.50% |
| Return on Equity | 3.85% |
| Return on Assets | 4.20% |
| Revenue/Share (TTM) | $10.05 |
| Book Value | $10.79 |
| Price-to-Book | 3.91 |
| Price-to-Sales (TTM) | 4.11 |
| EV/Revenue | 4.787 |
| EV/EBITDA | 36.62 |
| Quarterly Earnings Growth (YoY) | -99.40% |
| Quarterly Revenue Growth (YoY) | 27.00% |
| Shares Outstanding | $167.76M |
| Float | $155.19M |
| % Insiders | 1.40% |
| % Institutions | 107.86% |
Volatility is currently expanding
ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
Alkermes plc is upgraded from Hold to Buy, driven by robust revenue growth, pipeline momentum, and strategic positioning in sleep and CNS disorders. Acquisition of Avadel and Lumryz launch propel >20% revenue growth in 2026; adjusted EBITDA guidance is $370–410M despite a GAAP net loss. Alixorexton's strong Phase 2 data in narcolepsy and IH, plus advancing orexin pipeline, underpin multi-billion-dollar long-term revenue potential.
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 11, 2026. Now in its ninth year, this competitive grant program is designed to support the next generation of researchers working on the front lines to advance our understanding of diseases in the field of neuroscience. Building on prior award cycles, the program will continue to accept applications related to s.
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026 revenue view.
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alkermes NASDAQ: ALKS reported second-quarter 2026 revenue of $496 million, supported by growth across its proprietary product portfolio and the first full-quarter contribution from LUMRYZ following the company's acquisition of Avadel. The company also highlighted progress across its orexin development pipeline and reiterated most of its full-year financial outlook.
Alkermes (ALKS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.52 per share a year ago.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALKS and any ticker you trade — then tracks every position and per-strategy win rate.
